Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of ...

GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from ...

Finally, for its ASCO ‘Super Sunday’ hat trick, AZ and Daiichi Sankyo reported results from the DESTINY-Breast06 trial, which ...

Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its ...

At the ASCO congress in Chicago today, the results of the ASC4FIRST trial of Scemblix (asciminib) in people recently ...

Novartis’ anti-IgE antibody Xolair (omalizumab) has been a mainstay of treatment for refractory CSU for many years. However, ...

Slowly but surely, the world’s antibiotics are becoming less effective as disease-causing bacteria evolve into drug-resistant ...

Approval by the European Commission generally follows a few weeks after a CHMP decision, and that situation contrasts with ...

The FDA sent the Japanese pharma a complete response letter (CRL) in January saying it was unable to approve zolbetuximab as ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial ...

Elliot Pfebve (55) received the experimental vaccine at University Hospitals Birmingham NHS Foundation Trust, one of several ...

Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s ...